‘Velcade Inj,’ soon to be expired in patent, attracts interests of 3 companies, such as Chong Kun Dang

Expiring on the 28^th, the patent of ‘Velcade Inj(generic name: bortezomib),’ a Janssen Korea’s multiple myeloma treatment, has attracted attention of domestic pharmaceutical companies.

According to the Ministry of Food and Drug Safety, Chong Kun Dang, Boryung Pharm and Samyang Biopharmaceuticals completed preparation to target the market after acquiring product approvals.

The last year’s annu...